https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

injectable
Conference Coverage

The Monthly Injectable HIV Drug Works Just as Well When Given Every Two Months

Although injectable cabotegravir/rilpivirine is still yet to be approved by the FDA, evidence keeps mounting on the effectiveness of the shot for HIV treatment.

stem cell transplant device
Conference Coverage

Durable HIV Remission in London Patient, the Second Person Cured of HIV

Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.

injectable
News

Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable

Questions still remain as to when FDA will approve, and how it will be implemented.

Marrazzo at CROI
News

CROI 2020: What to Expect in HIV Science From This Year’s Conference

COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.

pregnant woman and partner cuddling on couch
News

New Study Will Test Safety of PrEP and Dapivirine Ring in Pregnancy

While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.

doctor getting ready to give patient vaccine
News Analysis

HIV Vaccine Trial Stopped Early, but Research Into Other Approaches Continues

HVTN 702 is but one of many vaccine trials underway, researchers note.

Toby Pepperrell
Interviews

Is Virologic Failure the Best Endpoint in Clinical Trials for Integrase Inhibitors?

Using data from the ADVANCE trial, this researcher suggests people with HIV with low-level viremia may still get to undetectable.

syringe going into vial
News Analysis

FDA Rejects Injectable HIV Treatment, but Not Due to Drug Safety

This may be a temporary setback, but long-acting antiretroviral therapy is still on the way, experts say.

Long-Acting Antiretrovirals photo illo
Features

ATLAS, FLAIR, and the Upcoming Arrival of Long-Acting Injectable HIV Treatment

The likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go?

Islatravir photo illo
Features

Islatravir Is Potent and Long-Lasting -- and May Be Having an Identity Crisis

This is clearly an antiretroviral not built for daily administration. But then what is it destined for?